Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients

Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients

Abstract Background and Aim Tenofovir disoproxil fumarate (TDF) has been efficacious in treating chronic hepatitis B (CHB), but long‐term use is accompanied by a decline in renal function and bone mineral density (BMD). Tenofovir alefanamide (TAF) is a prodrug of tenofovir, with similar efficacy in...

Full description

Bibliographic Details
Main Authors: Brian T Lee, Mimi Chang, Carolina Lim, Ho S Bae, Tse‐Ling Fong
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:JGH Open
Subjects:
bone mineral density
chronic hepatitis B
proximal tubular function
switch
tenofovir alafenamide
Online Access:https://doi.org/10.1002/jgh3.12481

Internet

https://doi.org/10.1002/jgh3.12481

Similar Items